Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (201-210 of 501) with videos related to

Pageof 51
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 26, 2008
Short German guidelines: squamous cell carcinomaHelmut Breuninger, Friedrich Bootz, Axel Hauschild, et al.
Journal of the American Academy of Dermatology|July 6, 2007
A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinomaThomas K Eigentler, Anne Kamin, Benjamin M Weide, et al.
Cancer|June 22, 2010
High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanomaBenjamin Weide, Evelyna Derhovanessian, Annette Pflugfelder, et al.
International Journal of Dermatology|January 20, 2011
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitorsYevgeniy Balagula, Claus Garbe, Patricia L Myskowski, et al.
Targeted Oncology|February 8, 2021
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF InhibitorsMaximilian Gassenmaier, Max M Lenders, Andrea Forschner, et al.
Plos One|November 28, 2017
Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanomaMaria Rita Gaiser, Alexander Skorokhod, Diana Gransheier, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 24, 2017
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy startFerdinand Seith, Andrea Forschner, Holger Schmidt, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 16, 2021
Theresa Steeb, Markus Follmann, Thomas Langer, et al.
Acta Dermato-Venereologica|September 7, 2021
Micrographic Surgery Allows Fascia Preservation in Dermatofibro-sarcoma ProtuberansMaximilian Gassenmaier, Erik Weber, Ulrike Leiter, et al.
International Journal of Cancer|February 11, 2012
Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cellsSarah Schott, Heike Niessner, Tobias Sinnberg, et al.
Pageof 51

Showing results (201-210 of 501) with videos related to

Sort By:
Pageof 51
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 26, 2008
Short German guidelines: squamous cell carcinomaHelmut Breuninger, Friedrich Bootz, Axel Hauschild, et al.
Journal of the American Academy of Dermatology|July 6, 2007
A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinomaThomas K Eigentler, Anne Kamin, Benjamin M Weide, et al.
Cancer|June 22, 2010
High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanomaBenjamin Weide, Evelyna Derhovanessian, Annette Pflugfelder, et al.
International Journal of Dermatology|January 20, 2011
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitorsYevgeniy Balagula, Claus Garbe, Patricia L Myskowski, et al.
Targeted Oncology|February 8, 2021
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF InhibitorsMaximilian Gassenmaier, Max M Lenders, Andrea Forschner, et al.
Plos One|November 28, 2017
Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanomaMaria Rita Gaiser, Alexander Skorokhod, Diana Gransheier, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 24, 2017
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy startFerdinand Seith, Andrea Forschner, Holger Schmidt, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 16, 2021
Theresa Steeb, Markus Follmann, Thomas Langer, et al.
Acta Dermato-Venereologica|September 7, 2021
Micrographic Surgery Allows Fascia Preservation in Dermatofibro-sarcoma ProtuberansMaximilian Gassenmaier, Erik Weber, Ulrike Leiter, et al.
International Journal of Cancer|February 11, 2012
Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cellsSarah Schott, Heike Niessner, Tobias Sinnberg, et al.
Pageof 51